Key Points
- EVP Andrew Callos sold 26,000 shares on March 5 at an average price of $61.87 for about $1.61 million, reducing his position by 34.01% to 50,440 shares (≈$3.12M).
- Callos has repeatedly sold stock over recent months — including a large sale of 52,486 shares on Dec. 5 — indicating a sustained insider sell-off.
- Cytokinetics traded near $60.91$7.5 billion; the company reported Q4 EPS of ($1.50) (slightly below estimates) but revenue of $17.76M beat expectations, and analysts hold a "Moderate Buy" consensus with a $89.28 average target.
Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Andrew Callos sold 26,000 shares of the firm's stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $61.87, for a total value of $1,608,620.00. Following the completion of the transaction, the executive vice president owned 50,440 shares of the company's stock, valued at approximately $3,120,722.80. The trade was a 34.01% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Andrew Callos also recently made the following trade(s):
- On Thursday, February 5th, Andrew Callos sold 15,000 shares of Cytokinetics stock. The shares were sold at an average price of $61.93, for a total value of $928,950.00.
- On Monday, February 2nd, Andrew Callos sold 886 shares of Cytokinetics stock. The stock was sold at an average price of $62.10, for a total transaction of $55,020.60.
- On Monday, January 5th, Andrew Callos sold 15,000 shares of Cytokinetics stock. The shares were sold at an average price of $60.28, for a total transaction of $904,200.00.
- On Friday, January 2nd, Andrew Callos sold 1,798 shares of Cytokinetics stock. The stock was sold at an average price of $62.62, for a total transaction of $112,590.76.
- On Monday, December 29th, Andrew Callos sold 1,809 shares of Cytokinetics stock. The stock was sold at an average price of $62.44, for a total value of $112,953.96.
- On Monday, December 8th, Andrew Callos sold 1,042 shares of Cytokinetics stock. The stock was sold at an average price of $65.96, for a total value of $68,730.32.
- On Friday, December 5th, Andrew Callos sold 52,486 shares of Cytokinetics stock. The shares were sold at an average price of $65.95, for a total transaction of $3,461,451.70.
Cytokinetics Price Performance
Shares of CYTK stock traded down $1.28 during mid-day trading on Friday, hitting $60.91. The company had a trading volume of 444,430 shares, compared to its average volume of 1,798,550. The company has a market capitalization of $7.50 billion, a P/E ratio of -9.33 and a beta of 0.56. The stock's 50 day moving average price is $64.01 and its 200-day moving average price is $59.27. Cytokinetics, Incorporated has a 52-week low of $29.31 and a 52-week high of $70.98.
Cytokinetics (NASDAQ:CYTK - Get Free Report) last announced its quarterly earnings results on Tuesday, February 24th. The biopharmaceutical company reported ($1.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.48) by ($0.02). The business had revenue of $17.76 million for the quarter, compared to the consensus estimate of $8.02 million. During the same quarter in the prior year, the company posted ($1.26) EPS. The business's revenue was up 4.9% compared to the same quarter last year. On average, equities research analysts expect that Cytokinetics, Incorporated will post -5.24 earnings per share for the current year.
Wall Street Analysts Forecast Growth
CYTK has been the subject of several research analyst reports. Barclays started coverage on Cytokinetics in a report on Wednesday, January 28th. They set an "overweight" rating and a $87.00 price target for the company. Bank of America reiterated a "neutral" rating on shares of Cytokinetics in a research report on Wednesday, February 25th. Weiss Ratings restated a "sell (d-)" rating on shares of Cytokinetics in a research report on Wednesday, January 21st. Citigroup reiterated a "market outperform" rating on shares of Cytokinetics in a research report on Monday, December 22nd. Finally, Citizens Jmp lifted their price objective on shares of Cytokinetics from $88.00 to $96.00 and gave the stock a "market outperform" rating in a research note on Wednesday, February 25th. Seventeen equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $89.28.
View Our Latest Report on CYTK
Hedge Funds Weigh In On Cytokinetics
Several hedge funds have recently bought and sold shares of the business. Seven Fleet Capital Management LP bought a new stake in shares of Cytokinetics during the fourth quarter worth $657,000. Alpine Global Management LLC purchased a new position in Cytokinetics in the 4th quarter worth about $381,000. Pacer Advisors Inc. lifted its holdings in Cytokinetics by 76.5% during the 4th quarter. Pacer Advisors Inc. now owns 27,783 shares of the biopharmaceutical company's stock valued at $1,765,000 after buying an additional 12,043 shares in the last quarter. Invesco Ltd. boosted its position in Cytokinetics by 30.3% in the 4th quarter. Invesco Ltd. now owns 204,878 shares of the biopharmaceutical company's stock valued at $13,018,000 after buying an additional 47,629 shares during the period. Finally, Corient Private Wealth LLC grew its stake in Cytokinetics by 527.1% in the 4th quarter. Corient Private Wealth LLC now owns 30,184 shares of the biopharmaceutical company's stock worth $1,918,000 after acquiring an additional 25,371 shares in the last quarter.
Cytokinetics Company Profile
(
Get Free Report)
Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.
The company's most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
